Quarterly ResultMay 8, 2026, 08:17 AM
ALX Oncology Q1 Net Loss Narrows to $17.9M; Equity Offering Raises $140.3M
AI Summary
ALX Oncology Holdings Inc. reported a significantly reduced net loss of $17.9 million for Q1 2026, an improvement from $30.8 million in Q1 2025, with diluted EPS improving to $(0.17) from $(0.58). This financial improvement was supported by a substantial equity offering that raised $140.3 million, net of costs, significantly bolstering the company's cash and investment position. The company believes its existing capital resources are sufficient for at least the next twelve months.
Key Highlights
- Q1 2026 net loss narrowed to $17.9 million from $30.8 million in Q1 2025.
- Diluted net loss per share improved to $(0.17) in Q1 2026 from $(0.58) in Q1 2025.
- Total operating expenses decreased to $19.0 million in Q1 2026 from $31.8 million in Q1 2025.
- Research and development expenses fell to $13.6 million from $23.9 million year-over-year.
- General and administrative expenses decreased to $5.4 million from $7.9 million year-over-year.
- Cash and cash equivalents increased to $32.3 million as of March 31, 2026, from $16.4 million.
- Total assets rose to $178.3 million as of March 31, 2026, from $59.0 million.
- Equity offerings generated $140.3 million, net of costs, in Q1 2026.
- Company expects existing capital to fund operations for at least the next 12 months.